icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
GNhNGKUBZLVW7Av5